Trial Profile
Phase4, to Assess Time to Progression (TTP) and Safety Profile of Doxorubicin-Eluting-Bead Embolization(DEBDOX) in Patients With Advanced HCC
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Jan 2020
Price :
$35
*
At a glance
- Drugs Doxorubicin (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms DCbead-PVTT
- 15 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 23 Oct 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 20 Aug 2015 New trial record